针对性和无化疗方法在HER2-阳性早期乳腺癌:系统性审查和元分析
Zaheer Qureshi1, Abdur Jamil2, Navkirat Kahlon3
1Department of Internal Medicine, School of Medicine at Quinnipiac University, Bridgeport, CT.
American journal of clinical oncology
|December 8, 2025
概括
无化疗疗法对HER2阳性早期乳腺癌有希望,具有良好的生存率和类似的安全性. 然而,化学疗法与抗HER2药物相结合,提供了优越的临床结果.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 在没有治疗的情况下,HER2阳性乳腺癌呈现出侵略性生长和不良预后.
- 无化疗方案正在成为改善早期HER2阳性乳腺癌的治疗结果的策略.
- 评估这些新疗法的疗效和安全性对于治疗优化至关重要.
研究的目的:
- 为了评估无化疗方案的疗效和安全性,在患有HER2阳性早期乳腺癌的患者.
- 为了比较无化疗和常规化疗方案之间的治疗结果.
- 分析病理完整反应 (pCR),无侵袭性疾病生存率 (iDFS) 和无事件生存率 (EFS).
主要方法:
- 在主要数据库 (PubMed,CENTRAL,Google Scholar,Embase) 进行了系统的文献搜索,截至2024年7月.
- 包括五项随机试验,涉及1489名HER2-阳性乳腺癌早期患者.
- 使用元分析汇集了关于治疗疗效和安全结果的数据.
主要成果:
- 大约有26.1%的无化疗方案的患者实现了pCR.
- 无化疗方案显示高3年和5年iDFS (95.40%,85.71%) 和5年EFS (81.13%).
- 由于不良事件导致的中止率在无化疗和常规组之间相似 (OR:0.29,P=0.18),但与化疗加抗HER2药物相比,pCR较差.
结论:
- 无化疗方案显示了HER2阳性早期乳腺癌的令人鼓舞的疗效和生存益处.
- 尽管有希望的安全性,但化学疗法与抗HER2药物相结合仍然在实现整体临床结果方面优越.
- 进一步的研究可能会为特定患者群体完善无化疗策略.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.4K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.5K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K